Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Blood (2019) 133 (19): 2031–2042.

https://doi.org/10.1182/blood-2018-08-870238

Published: 2019

Includes: Supplemental data

Journal Articles

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Saad Ahmed, MBBS, Mattia Cremona, PhD, Sinead Toomey, PhD, Mark Catherwood, PhD, Stephen Bergin, BS, Paul Kennedy, BS, Bryan Hennessy, MD, Patrick Thornton, MB, FRCPath, John Quinn, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 5532.

https://doi.org/10.1182/blood-2018-99-114104

Published: 2018

Journal Articles

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Aisling Barrett, John Quinn, MD PhD, Siobhan Glavey, MD PhD, Jeremy Sargent, FRCPath, Michelle Lavin, MB, PhD FRCPath, Patrick Thornton, MB, FRCPath, James S O'Donnell, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 1223.

https://doi.org/10.1182/blood-2018-99-116148

Published: 2018

Journal Articles

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

Saad Ahmed, MBBS, MRCP, John Quinn, Mark Catherwood, Patrick Thornton, Stephen Bergin, Paul Kennedy, Sally Elsir, Bryan Hennessy, Philip Murphy

Blood (2017) 130 (Supplement 1): 5323.

https://doi.org/10.1182/blood.V130.Suppl_1.5323.5323

Published: 2017

Journal Articles

From a DOAC to Warfarin: Reasons Why Patients Switch

Aisling Barrett, MB, BCh, BAO, MRCPI, Sahar Khan, MRCPI, Margaret Moore, RGN, Patricia Ferrins, RGN, BSc, Jeremy Sargent, FRCPath, Patrick Thornton, Philip Murphy, John Quinn

Blood (2017) 130 (Supplement 1): 4910.

https://doi.org/10.1182/blood.V130.Suppl_1.4910.4910

Published: 2017

Journal Articles

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

Helen Fogarty, Anita Dowling, David O'Brien, Christopher Laurence Bacon, Patrick Thornton, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Gerard Crotty, Robert Henderson, James Nolan, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD, Fiona M Quinn, PhD

Blood (2016) 128 (22): 5569.

https://doi.org/10.1182/blood.V128.22.5569.5569

Published: 2016

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Sally Elsir Mohammed, MBBS, MRCP(UK), Philip Murphy, MD, John Quinn, Patrick Thornton, FRCPath, Stephen Bergin, Bryan Hennessy

Blood (2015) 126 (23): 5271.

https://doi.org/10.1182/blood.V126.23.5271.5271

Published: 2015

Journal Articles

Prognostic Significance of WT1 and PRAME Gene Expression in Bone Marrow Samples of MDS and AML Patients Treated with Azacytidine

Claire N Andrews, MB BAO BCh LRCPI SI MRCPI, Karen Murphy, FRCP, FRCPath, Sinead Moran, Patrick Thornton, Nichola Harten, Philip T Murphy, MD MRCPath

Blood (2014) 124 (21): 5599.

https://doi.org/10.1182/blood.V124.21.5599.5599

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

Impact Of Dialysis-Dependent Renal Failure At Time Of Myeloma Diagnosis On Overall Survival - a 15-Year Single Centre Analysis

Philip T Murphy, MD, MRCPath, Cherisse Baldeo, MB, Patrick O'Kelly, Jeremy Sargant, MB, Patrick Thornton, MB, Mary McCloy, MB, MRCP, MRCPath, Peter Conlon, MB, Colm Magee, MB, Mark Denton, MB, John Quinn, MB, PhD

Blood (2013) 122 (21): 3230.

https://doi.org/10.1182/blood.V122.21.3230.3230

Published: 2013

NARROW

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

From a DOAC to Warfarin: Reasons Why Patients Switch

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Prognostic Significance of WT1 and PRAME Gene Expression in Bone Marrow Samples of MDS and AML Patients Treated with Azacytidine

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Impact Of Dialysis-Dependent Renal Failure At Time Of Myeloma Diagnosis On Overall Survival - a 15-Year Single Centre Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only